Perceived or actual barriers to warfarin use in atrial fibrillation based on electronic medical records

American Journal of Therapeutics

Volumn 19, Issue 5, 2012, Pages 330-337

  Rosenman, Marc B ^a,b   Simon, Teresa A ^c   Teal, Evgenia ^b   McGuire, Patricia ^b   Nisi, Daniel ^b   Jackson, Joseph D ^d  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b REGENSTRIEF INSTITUTE   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

atrial fibrillation; barriers to use; CHADS2; contraindications; warfarin

Indexed keywords

WARFARIN;

ADULT; AGED; ALCOHOL ABUSE; ARTICLE; BRAIN HEMORRHAGE; CLINICAL PRACTICE; DRUG CONTRAINDICATION; DRUG USE; ELECTRONIC MEDICAL RECORD; FALL RISK; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HEPATITIS; HUMAN; ICD-9; KIDNEY FAILURE; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; COHORT STUDIES; ELECTRONIC HEALTH RECORDS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; WARFARIN;

EID: 84866405525     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3182546840     Document Type: Article

References (39)

1. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med. 1990;323:1505-1511.
2. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet. 1993;342:1255-1262.
3. Hart RG, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999;131:492-501.
4. Granger CB, McMurray JJ. Using measures of disease progression to determine therapeutic effect: a sirens' song. J Am Coll Cardiol. 2006;48:434-437.
5. Tamura L. Sanguine hopes for newer, safer blood thinners [Washington Post 11/23/2010]. Available at: http://www. washingtonpost.com/wp-dyn/content/ article/2010/11/19/AR2010111906348.html. Accessed December 19, 2010.
6. Fuster V, Rydén LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol. 2011;57:e101-e198.
7. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864-2870.
8. O'Donnell M, Oczkowski W, Fang J, et al. Preadmission antithrombotic treatment and stroke severity in patients with atrial fibrillation and acute ischaemic stroke: an observational study. Lancet Neurol. 2006;5:749-754.
9. Gladstone DJ, Bui E, Fang J, et al. Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke. 2009;40:235-240.
10. Majeed A, Moser K, Carroll K. Trends in the prevalence and management of atrial fibrillation in general practice in England and Wales, 1994-1998: analysis of data from the general practice research database. Heart. 2001;86:284-288.
11. DeWilde S, Carey IM, Emmas C, et al. Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulation and predictors of such treatment in UK primary care. Heart. 2006;92:1064-1070.
12. Fang MC, Stafford RS, Ruskin JN, et al. National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation. Arch Intern Med. 2004;164:55-60.
13. Birman-Deych E, Radford MJ, Nilasena DS, et al. Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation. Stroke. 2006;37:1070-1074.
14. Gattellari M, Worthington JM, Zwar NA, et al. The management of non-valvular atrial fibrillation (NVAF) in Australian general practice: bridging the evidence-practice gap. A national, representative postal survey. BMC Fam Pract. 2008;9:62.
15. Choudhry NK, Anderson GM, Laupacis A, et al. Impact of adverse events on prescribing warfarin in patients with atrial fibrillation: matched pair analysis. BMJ. 2006;332:141-145.
16. Lipman T, Murtagh MJ, Thomson R. How research conscious GPs make decisions about anticoagulation in patients with atrial fibrillation: a qualitative study. Fam Pract. 2004;21:290-298.
17. Man-Son-Hing M, Gage BF, Montgomery AA, et al. Preference-based antithrombotic therapy in atrial fibrillation: implications for clinical decision-making. Med Decis Making. 2005;25:548-559.
18. McAlister FA, Man-Son-Hing M, Straus SE, et al. Impact of a patient decision aid on care among patients with nonvalvular atrial fibrillation: a cluster randomised trial. CMAJ. 2005;173:496-501.
19. Nochowitz B, Shapiro NL, Nutescu EA, et al. Effect of a warfarin adherence aid on anticoagulation control in an inner-city anticoagulation clinic population. Ann Pharmacother. 2009;43:1165-1172.
20. Siebenhofer A, Berghold A, Sawicki PT. Systematic review of studies of self-management of oral anticoagulation. Thromb Haemost. 2004;91:225-232.
21. Kowey PR, Reiffel JA, Myerburg R, et al. Warfarin and aspirin use in atrial fibrillation among practicing cardiologist (from the AFFECTS Registry). Am J Cardiol. 2010; 105:1130-1134.
22. Waldo AL, Becker RC, Tapson VF, et al. Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. J Am Coll Cardiol. 2005;46:1729-1736.
23. Piccini JP, Hernandez AF, Zhao X, et al. Quality of care for atrial fibrillation among patients hospitalized for heart failure. J Am Coll Cardiol. 2009;54:1280-1289.
24. Friberg L, Hammar N, Ringh M, et al. Stroke prophylaxis in atrial fibrillation: who gets it and who does not? Report from the Stockholm Cohort-study on Atrial Fibrillation (SCAF-study). Eur Heart J. 2006;27:1954-1964.
25. Monette J, Gurwitz JH, Rochon PA, et al. Physician attitudes concerning warfarin for stroke prevention in atrial fibrillation: results of a survey of long-term care practitioners. J Am Geriatr Soc. 1997;45:1060-1065.
26. Boulanger L, Hauch O, Friedman M, et al. Warfarin exposure and the risk of thromboembolic and major bleeding events among Medicaid patients with atrial fibrillation. Ann Pharmacother. 2006;40:1024-1029.
27. Johnston JA, Cluxton RJ Jr, Heaton PC, et al. Predictors of warfarin use among Ohio Medicaid patients with new-onset nonvalvular atrial fibrillation. Arch Intern Med. 2003;163:1705-1710.
28. Hylek EM. Trends in anticoagulation management across community-based practices in the United States: the Anticoagulation Consortium to Improve Outcomes Nationally (ACTION) study. J Thromb Thrombolysis. 2003;16:83-86.
29. Go AS, Hylek EM, Chang Y, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA. 2003;290:2685-2692.
30. Glazer NL, Dublin S, Smith NL, et al. Newly detected atrial fibrillation and compliance with antithrombotic guidelines. Arch Intern Med. 2007;167:246-252.
31. McDonald CJ, Overhage JM, Tierney WM, et al. The Regenstrief Medical Record System: a quarter century experience. Int J Med Inform. 1999;54:225-253.
32. Steinwachs DM, Stuart ME, Scholle S, et al. A comparison of ambulatory Medicaid claims to medical records: a reliability assessment. Am J Med Qual. 1998;13:63-69.
33. McDonald CJ, Tierney WM. The MedicalGopher-amicrocomputer system to help find, organize and decide about patient data. West J Med. 1986;145:823-829.
34. Odero WW, Tierney WM, Einterz RM, et al. Using an electronic medical record system to describe injury epidemiology and health care utilization at an inner-city hospital in Indiana. Inj Control Saf Promot. 2004;11:269-279.
35. Chalasani N, Saha C, Teal E. Are there ethnicity-based differences in the evaluation of individuals with abnormal liver biochemistries? J Hepatol. 2007;47:123-127.
36. Azoulay L, Simon TA, Dell'Aniello S, et al. Optimal warfarin anticoagulation and the prevention of stroke in patients with atrial fibrillation: a population-based study. Eur Heart J. 2010;31(Abstract Supplement):155.
37. Fitzmaurice DA, Blann AD, Lip GY. Bleeding risks of antithrombotic therapy. BMJ. 2002;325:828-831.
38. Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results for the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006;151:713-719.
39. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on Atrial Fibrillation. Chest. 2010;137:263-272.